v3.25.4
Reverse Recapitalization and Sonnet Acquisition - Summary of Cost of Acquisition and Allocation to Assets Acquired and Liabilities Assumed (Details) - Sonnet BioTherapeutics Holdings, Inc. [Member]
$ in Thousands
Jul. 11, 2025
USD ($)
Assets Acquired and Liabilities Assumed  
Cash $ 10,347
Assembled workforce 800
In-process research and development 35,605
Other assets 1,788
Accounts payable (2,707)
Accrued expenses and other current liabilities (999)
Total net assets acquired 44,834
Cost of the Acquisition  
Fair value of common stock issued 17,800
Total consideration paid to Sonnet 35,510
Transaction costs 9,324
Total cost of the acquisition 44,834
Common Stock [Member]  
Cost of the Acquisition  
Fair value of common stock issued 17,771
Warrant [Member]  
Cost of the Acquisition  
Fair value of common stock issued 12,478
Cash to settle outstanding Sonnet warrants $ 5,261